EGFR tyrosine kinase inhibitors for lung cancer

A tyrosine kinase is part of a cell signalling pathway. When a tumour has a susceptible EGFR change, an inhibitor can block that signal and slow or shrink cancer activity. The medicine is selected after genomic tumour profiling and is usually taken according to a regular schedule. It is not suitable for every lung cancer, and the exact alteration matters.

The plan depends on stage, previous treatment, other illnesses, medicines, and the treatment goal. Scans and clinical reviews show whether the cancer is responding or whether the plan needs to change.

Take each dose as directed and ask what to do if you miss one. Tell the team about prescription medicines, antacids, herbal products, and supplements before starting or adding them. Keep a record of bowel changes, skin changes, appetite, vision, and breathing. Regular checks can help manage side effects before they interfere with daily activities.

Seek prompt guidance for severe diarrhoea, repeated vomiting, a painful or infected-looking rash, eye pain or vision changes, fainting, marked swelling, or reduced urine. Call urgently for new breathlessness, chest pain, blue lips, confusion, or sudden neurological symptoms. A new hoarse voice should also be discussed, especially if it persists or worsens.

Which EGFR change was detected? How should I take this inhibitor with my other medicines? Which side effects are expected, and which require urgent contact? What monitoring will I need, and what is the next option if the cancer changes?